IGF-1 — insulin-like growth factor 1 — is the liver-derived downstream signal that makes GH-axis research measurable. You cannot observe GH pulsatility directly in a living subject without continuous blood sampling; but you can draw a single morning IGF-1 and get a reliable proxy for GH secretory tone across the previous 24 hours. This is why tesamorelin's IGF-1 footprint is so well-documented: every major clinical study used IGF-1 as an on-protocol biomarker, not just an endpoint. The result is a dataset that researchers can actually use when designing 1mg vs 2mg titration protocols. Below is what that dataset shows, stripped of clinical framing and translated into research-context terms for investigators working in the UAE or sourcing peptides UAE-wide.
Tesamorelin is a synthetic GHRH analog — specifically, a 44-amino-acid peptide identical to endogenous GHRH 1-44 with a trans-3-hexenoyl modification at the N-terminus. That structural addition serves two functions: it blocks rapid cleavage by dipeptidyl peptidase-IV (DPP-IV) in plasma, extending the peptide's functional half-life from under two minutes (native GHRH) to roughly 30-40 minutes; and it preserves the receptor-binding conformation that triggers GH release from somatotroph cells in the anterior pituitary.
The cascade is linear: tesamorelin binds pituitary GHRH receptors → stimulates pulsatile GH secretion → GH signals the liver to produce IGF-1 → circulating IGF-1 rises proportionally. Critically, tesamorelin works within normal physiological feedback — it does not suppress the GHRH-GH-IGF-1 axis in the way exogenous GH does, and it preserves the negative-feedback role of somatostatin. This means IGF-1 rises follow the curve of increased GH pulsatility, not a blunt pharmacological override. For investigators studying GH-axis modulation, this distinction is meaningful: tesamorelin's IGF-1 response reflects amplified physiology, not replacement pharmacology.
The first and most cited landmark is Falutz et al. 2007, published in the New England Journal of Medicine. The investigators enrolled 412 HIV-positive adults with confirmed abdominal fat accumulation — a metabolically relevant phenotype characterised by excess visceral adipose tissue (VAT). Subjects were randomised to tesamorelin 2mg SC daily or placebo for 26 weeks.
The IGF-1 findings:
From a research-design standpoint, this is the foundational 2mg/day reference: 412 subjects, 26 weeks, pre-specified IGF-1 endpoint, large enough to establish a dose-response floor. If an investigator's protocol references "the Falutz dose," it means 2mg SC once daily in the evening.
The 2010 follow-up published in the Journal of Clinical Endocrinology & Metabolism extended the Falutz 2007 responder cohort through an additional 26 weeks, giving a 52-week total duration window. The key questions for IGF-1 researchers:
For investigators planning protocol durations beyond 12 weeks, the 2010 data provides the strongest published evidence that tesamorelin-driven IGF-1 elevation does not self-limit within a six-month window.
The Stanley group at Massachusetts General Hospital extended tesamorelin research into a different metabolic endpoint — non-alcoholic fatty liver disease (NAFLD) in HIV-positive adults. These two trials matter for IGF-1 researchers because they confirm the same downstream IGF-1 response in a separate disease model, and they add a mechanistically meaningful secondary finding.
74 HIV-positive subjects with confirmed NAFLD were randomised to tesamorelin 2mg/day or placebo for 12 months. Liver fat — measured by MR spectroscopy — fell by 32% relative to placebo in the tesamorelin arm. IGF-1 rose in parallel with the GH-axis stimulation pattern observed in the Falutz cohorts. Crucially, the investigators noted that IGF-1 normalization (from below-normal baseline in this HIV cohort) appeared to correlate with the degree of hepatic fat reduction, raising the hypothesis that IGF-1 itself may mediate some of the NAFLD benefit independently of the direct lipolytic action of GH.
The 2019 follow-up expanded the NAFLD dataset with a larger, 12-month randomised multicentre design. Tesamorelin's IGF-1 effect was replicated with high consistency across sites — reinforcing that the ~50% IGF-1 rise at 2mg/day is a stable pharmacodynamic signature, not a cohort-specific artefact. The liver-fat reduction was again statistically significant versus placebo. Together with the Falutz data, this gives investigators four independent datasets across two distinct disease models — all using 2mg/day SC as the reference dose.
The published clinical literature used 2mg/day as the pivotal dose across all four major trials. The 1mg/day tier does not have a dedicated large-scale IGF-1 endpoint study in the same published literature. However, what the existing data allows researchers to infer:
| Research Dose Tier | Published IGF-1 Data | Typical Onset | Protocol Duration Reference |
|---|---|---|---|
| 1mg/day SC | Not directly studied in pivotal trials; partial response inferred from receptor pharmacology | 4-8 weeks (investigator reports) | Used as titration entry in some research designs |
| 2mg/day SC | ~50% IGF-1 rise at 26 weeks (Falutz 2007 NEJM); sustained at 52 weeks (Falutz 2010) | Significant rise by week 13; peak ~week 26 | 26-52 week protocols; JAMA 2014, Lancet HIV 2019 |
REVIVE LAB UAE supplies tesamorelin in two vial sizes: 5mg and 10mg. Both are lyophilized, HPLC-verified, and shipped with lot-specific COA. The reconstitution math for 1mg/day and 2mg/day research protocols is straightforward:
| Vial Size | BAC Water Added | Concentration | 1mg Dose Volume | 2mg Dose Volume | Days Supply (2mg/day) |
|---|---|---|---|---|---|
| Tesamorelin 5mg | 1 mL | 5mg/mL | 0.20 mL (20 IU) | 0.40 mL (40 IU) | 2.5 days |
| Tesamorelin 5mg | 2 mL | 2.5mg/mL | 0.40 mL (40 IU) | 0.80 mL (80 IU) | 2.5 days |
| Tesamorelin 10mg | 2 mL | 5mg/mL | 0.20 mL (20 IU) | 0.40 mL (40 IU) | 5 days |
| Tesamorelin 10mg | 4 mL | 2.5mg/mL | 0.40 mL (40 IU) | 0.80 mL (80 IU) | 5 days |
The 10mg vial is the more economical choice for investigators running the full 2mg/day Falutz reference protocol over 26 weeks — it yields 5 days per vial versus 2.5 days for the 5mg. For the 1mg/day titration approach, the 5mg vial provides a clean 5-day supply at 5mg/mL concentration. Either format can be ordered through REVIVE LAB UAE with tesamorelin same day Dubai delivery or 24h emirate-wide dispatch.
Reconstitution best practice: add BAC water slowly down the inside wall of the vial — never directly onto the lyophilized cake. Swirl gently; do not vortex or shake. Store reconstituted vials at 2-8°C and use within 14 days. The Falutz and Stanley studies specified 2-8°C storage throughout; the published IGF-1 data is only valid for peptide that remained in spec.
One variable that introduces unexplained IGF-1 variance in research protocols — more than dose timing, injection site, or storage duration — is peptide purity. A nominal 2mg dose of 80% pure tesamorelin delivers approximately 1.6mg of active peptide; the remaining 20% is truncated fragments, oxidation products, or synthesis impurities that can act as receptor antagonists at the GHRH receptor, partially blunting the GH-axis response.
This is not a theoretical concern. GHRH receptor occupancy by non-functional fragments reduces the effective IGF-1 rise relative to what a clean 2mg dose would produce. Investigators who switch from an unverified source to an HPLC-certified supplier frequently observe IGF-1 responses that more closely match the Falutz 2007 reference curve — not because the dose changed, but because the effective dose changed.
REVIVE LAB UAE runs every tesamorelin batch through HPLC analysis targeting ≥99% purity. Lot-specific certificates of analysis are available on request. This is the same standard the clinical trial investigators used when they sourced tesamorelin for the NEJM, JAMA, and Lancet HIV studies — and it is the only standard that makes the published IGF-1 data reproducible in a research context.
REVIVE LAB UAE is a Dubai-based peptides UAE supplier with cold-chain courier infrastructure covering all seven emirates. Tesamorelin 5mg and 10mg are stocked in Dubai right now — not on a lead-time order from offshore. When you place an order before the daily cut-off, dispatch is same-day. The tesamorelin Dubai 24h delivery commitment is not a marketing claim; it is a function of the courier network being Dubai-local, not international drop-ship.
| Emirate / Region | Delivery Window | Cash on Delivery | Cold-Chain Packaging |
|---|---|---|---|
| Dubai (Marina, JBR, DIFC, Downtown, Palm, JVC, Business Bay, Jumeirah) | Same-day, 4-8 hours | Yes | Yes |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem Island) | Next-day, 18-24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8-18 hours | Yes | Yes |
| Ajman | Next-day, 18-24 hours | Yes | Yes |
| Ras Al Khaimah | Next-day, 18-24 hours | Yes | Yes |
| Fujairah | Next-day, 24 hours | Yes | Yes |
| Umm Al Quwain | Next-day, 18-24 hours | Yes | Yes |
Beyond tesamorelin, the REVIVE LAB UAE catalogue covers the broader peptides UAE research stack — Retatrutide, GHK-Cu, BPC-157, TB-500, MOTS-c, Semax, and NAD+. All products are HPLC-tested and cold-chain dispatched. For investigators focused on the GH-axis specifically, tesamorelin remains the flagship: it is the only GHRH analog with a four-study published IGF-1 dataset across two disease models, giving a reproducible research baseline that no other peptide in the UAE market can match.
The Falutz et al. 2007 NEJM trial — 412 subjects, 26 weeks at 2mg/day SC — reported a roughly 50% rise in IGF-1 from baseline versus a small decline in the placebo group. The 2010 26-week extension confirmed the IGF-1 response was sustained over 52 weeks total, with no tachyphylaxis at the 2mg/day dose. Subjects who crossed over from placebo to tesamorelin in the extension phase replicated the original IGF-1 rise within 13 weeks, confirming reproducibility of the dose-response signal. Investigators using tesamorelin in UAE-based research settings can reference this as the foundational benchmark.
REVIVE LAB UAE stocks tesamorelin 5mg and 10mg vials — both HPLC-verified to ≥99% purity, with lot-specific COA available on request and cold-chain packaging for every dispatch. To order, visit /buy-tesamorelin-uae/ and select your vial size and quantity. Dubai-area investigators (Marina, JBR, DIFC, Downtown, Palm, Business Bay, JVC, Jumeirah) receive tesamorelin same day Dubai delivery within 4-8 hours for orders placed before the daily cut-off. All other emirates are within 24 hours. Cash on delivery Dubai and UAE-wide is supported.
Based on the Falutz 2007 NEJM data, investigators observed statistically significant IGF-1 rises within 13 weeks of starting the 2mg/day SC protocol. The peak response was observed around week 26. The 2010 extension confirmed that IGF-1 levels returned toward baseline within weeks of discontinuation — confirming that GH-axis stimulation from tesamorelin is peptide-dependent and fully reversible. This reversibility is mechanistically consistent with tesamorelin's upstream, physiology-modulating mode of action (versus replacement GH), and it is a primary reason the compound remains a central subject in GHRH-axis research.